Zelluna ASA - Share Issue/Capital Change 2025

ZLNA - New registered share capital

Oslo, 27 May 2025: Zelluna ASA (the "Company") refers to the announcement on 24

May 2025 regarding a resolution by the Company's Board of Directors to issue

227,096 new shares in the Company against set-off of an option exercise fee.

The share capital increase related to the issuance of the new shares has now

been registered with the Norwegian Register of Business Enterprises, and the

Company's new registered share capital is NOK 20,454,162, divided into

20,454,162 shares, each with a par value of NOK 1.

For further information, please contact:

Hans Vassgård Eid, CFO, Zelluna ASA

Phone: +47 482 48632

About Zelluna ASA

Zelluna's mission is to deliver transformative treatments with the capacity to

cure advanced solid cancers, in a safe and cost-efficient manner, to patients on

a global scale. The Company aims to do this by combining the most powerful

elements of the immune system through pioneering the development of "off the

shelf" T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK).

The TCR-NK platform offers a unique mechanism of action with broad cancer

detection capability to overcome the diversity of tumours and will be used "off

the shelf" to overcome scaling limitations of current cell therapies. The lead

program is a world's first MAGE-A4 targeting "off the shelf" TCR-NK for the

treatment of various solid cancers; a pipeline of earlier products follows. The

Company is led by a management team of biotech entrepreneurs with deep

experience in discovery through to clinical development of TCR and cell-based

therapies including marketed products.

AI assistant